Breast Cancer: Recurrent Genomic Alterations: Difference between revisions

[unchecked revision][unchecked revision]
No edit summary
m Added some links
Line 211: Line 211:
|2
|2
|Gain of function
|Gain of function
|164757
|[https://omim.org/entry/164757 164757]
|BRAF
|[https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF BRAF]
|BRAF breast
|[https://www.cbioportal.org/results/oncoprint?cancer_study_list=acbc_mskcc_2015%2Cbreast_cptac_gdc%2Cbrca_hta9_htan_2022%2Cbrca_metabric%2Cbreast_msk_2025%2Cbreast_msk_2018%2Cbrca_pareja_msk_2020%2Cbrca_mskcc_2019%2Cbreast_alpelisib_2020%2Cbrca_smc_2018%2Cbrca_bccrc_xenograft_2014%2Cbfn_duke_nus_2015%2Cbrca_bccrc%2Cbrca_broad%2Cbrca_sanger%2Cbrca_tcga_pub2015%2Cbrca_tcga%2Cbrca_tcga_pub%2Cbrca_tcga_pan_can_atlas_2018%2Cbrca_tcga_gdc%2Cbrca_jup_msk_2020%2Cbrca_mapk_hp_msk_2021%2Cmbc_msk_2021%2Cbrca_aurora_2023%2Cbrca_dfci_2020%2Cbrca_igr_2015%2Cbreast_ink4_msk_2021%2Cilc_msk_2023%2Cbrca_cptac_2020%2Cbrca_mbcproject_wagle_2017%2Cbrca_mbcproject_2022%2Cbrca_fuscc_2020&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Cstructural_variants%2Ccna%2Cgistic&case_set_id=all&gene_list=BRAF&geneset_list=%20&tab_index=tab_visualize&Action=Submit&exclude_germline_mutations=true BRAF breast]
|sequence variants
|sequence variants
|Diseases: TNBC, adenoid cystic carcinoma; Therapy: BRAF, MEK inhibitors.
|Diseases: TNBC, adenoid cystic carcinoma; Therapy: BRAF, MEK inhibitors.
|26095796; 27135926; 32206360; 34818649; 36531075
|[https://pubmed.ncbi.nlm.nih.gov/26095796/ 26095796]; [https://pubmed.ncbi.nlm.nih.gov/27135926/ 27135926]; [https://pubmed.ncbi.nlm.nih.gov/32206360/ 32206360]; [https://pubmed.ncbi.nlm.nih.gov/34818649/ 34818649]; [https://pubmed.ncbi.nlm.nih.gov/36531075/ 36531075]
|-
|-
|''BRCA1''
|''BRCA1''
|1
|1
|Loss of function
|Loss of function
|113705
|[https://omim.org/entry/113705 113705]
|BRCA1
|[https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRCA1 BRCA1]
|BRCA1 breast
|[https://www.cbioportal.org/results/oncoprint?cancer_study_list=acbc_mskcc_2015%2Cbreast_cptac_gdc%2Cbrca_hta9_htan_2022%2Cbrca_metabric%2Cbreast_msk_2025%2Cbreast_msk_2018%2Cbrca_pareja_msk_2020%2Cbrca_mskcc_2019%2Cbreast_alpelisib_2020%2Cbrca_smc_2018%2Cbrca_bccrc_xenograft_2014%2Cbfn_duke_nus_2015%2Cbrca_bccrc%2Cbrca_broad%2Cbrca_sanger%2Cbrca_tcga_pub2015%2Cbrca_tcga%2Cbrca_tcga_pub%2Cbrca_tcga_pan_can_atlas_2018%2Cbrca_tcga_gdc%2Cbrca_jup_msk_2020%2Cbrca_mapk_hp_msk_2021%2Cmbc_msk_2021%2Cbrca_aurora_2023%2Cbrca_dfci_2020%2Cbrca_igr_2015%2Cbreast_ink4_msk_2021%2Cilc_msk_2023%2Cbrca_cptac_2020%2Cbrca_mbcproject_wagle_2017%2Cbrca_mbcproject_2022%2Cbrca_fuscc_2020&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Cstructural_variants%2Ccna%2Cgistic&case_set_id=all&gene_list=BRCA1&geneset_list=%20&tab_index=tab_visualize&Action=Submit&exclude_germline_mutations=true BRCA1 breast]
|sequence variants, epigenetic modification, other structural rearrangement
|sequence variants, epigenetic modification, other structural rearrangement
|Diseases: hereditary BC (high penetrance); TNBC; ovarian, other cancers. Associated with tandem duplicator phenotype, HRD. Therapy: PARP inhibitors, Prediction: reversion mutations in cfDNA resistant to PARP inhibitors.
|Diseases: hereditary BC (high penetrance); TNBC; ovarian, other cancers. Associated with tandem duplicator phenotype, HRD. Therapy: PARP inhibitors, Prediction: reversion mutations in cfDNA resistant to PARP inhibitors.
|20301425; 33471991; 28578601; 31421928; 28765325; 30110579
|[https://pubmed.ncbi.nlm.nih.gov/20301425/ 20301425]; [https://pubmed.ncbi.nlm.nih.gov/33471991/ 33471991]; [https://pubmed.ncbi.nlm.nih.gov/28578601/ 28578601]; [https://pubmed.ncbi.nlm.nih.gov/31421928/ 31421928]; [https://pubmed.ncbi.nlm.nih.gov/28765325/ 28765325]; [https://pubmed.ncbi.nlm.nih.gov/30110579/ 30110579]
|-
|-
|''BRCA2''
|''BRCA2''
|1
|1
|Loss of function
|Loss of function
|600185
|[https://omim.org/entry/600185 600185]
|BRCA2
|[https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRCA2 BRCA2]
|BRCA2 breast
|[https://www.cbioportal.org/results/oncoprint?cancer_study_list=acbc_mskcc_2015%2Cbreast_cptac_gdc%2Cbrca_hta9_htan_2022%2Cbrca_metabric%2Cbreast_msk_2025%2Cbreast_msk_2018%2Cbrca_pareja_msk_2020%2Cbrca_mskcc_2019%2Cbreast_alpelisib_2020%2Cbrca_smc_2018%2Cbrca_bccrc_xenograft_2014%2Cbfn_duke_nus_2015%2Cbrca_bccrc%2Cbrca_broad%2Cbrca_sanger%2Cbrca_tcga_pub2015%2Cbrca_tcga%2Cbrca_tcga_pub%2Cbrca_tcga_pan_can_atlas_2018%2Cbrca_tcga_gdc%2Cbrca_jup_msk_2020%2Cbrca_mapk_hp_msk_2021%2Cmbc_msk_2021%2Cbrca_aurora_2023%2Cbrca_dfci_2020%2Cbrca_igr_2015%2Cbreast_ink4_msk_2021%2Cilc_msk_2023%2Cbrca_cptac_2020%2Cbrca_mbcproject_wagle_2017%2Cbrca_mbcproject_2022%2Cbrca_fuscc_2020&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Cstructural_variants%2Ccna%2Cgistic&case_set_id=all&gene_list=BRCA2&geneset_list=%20&tab_index=tab_visualize&Action=Submit&exclude_germline_mutations=true BRCA2 breast]
|sequence variants, other structural rearrangement
|sequence variants, other structural rearrangement
|Diseases: hereditary BC (high penetrance); ER positive BC; ovarian & other cancers, HRD. Therapy: PARP inhibitors; Prediction: reversion mutations in cfDNA resistant to PARP inhibitors.
|Diseases: hereditary BC (high penetrance); ER positive BC; ovarian & other cancers, HRD. Therapy: PARP inhibitors; Prediction: reversion mutations in cfDNA resistant to PARP inhibitors.
|20301425; 33471991; 28578601; 31421928; 28765325; 30110579
|[https://pubmed.ncbi.nlm.nih.gov/20301425/ 20301425]; [https://pubmed.ncbi.nlm.nih.gov/33471991/ 33471991]; [https://pubmed.ncbi.nlm.nih.gov/28578601/ 28578601]; [https://pubmed.ncbi.nlm.nih.gov/31421928/ 31421928]; [https://pubmed.ncbi.nlm.nih.gov/28765325/ 28765325]; [https://pubmed.ncbi.nlm.nih.gov/30110579/ 30110579]
|-
|-
|''BRIP1''
|''BRIP1''